Thus, the ESC and STO-GM combination vaccine significantly increases the ratio of CD8+ T cells to Tregs and the percentages of CD8+CD25+ and CD8+IFN-γ+ effector cells within the tumors and are suggestive of efficient vaccine-induced, tumor-reactive immune system priming. The gene discussed is CD8A; the disease is neoplasm.